Neurology Specific Literature Search   
 
[home][thesaurus]
    
Click Here to return To Results

 

Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
See this aricle in Pubmed

Article Abstract
Rates of VZV infections in clinical trials were low with fingolimod, 0.5 mg/d, but higher than in placebo recipients. Rates reported in the postmarketing setting are comparable. We found no sign of risk accumulation with longer exposure. Serious or complicated cases of herpes zoster were uncommon. We recommend establishing the patient?s VZV immune status before initiating fingolimod therapy and immunization for patients susceptible to primary VZV infection. Routine antiviral prophylaxis is not needed, but using concomitant pulsed corticosteroid therapy beyond 3 to 5 days requires an individual risk-benefit assessment. Vigilance to identify early VZV symptoms is important to allow timely antiviral treatment.
 
Related Tags
(click to filter results - removes previous filter)

adverse drug reaction
antiviral agents
fingolimod
herpes zoster
infection
medication withdrawal
multiple sclerosis
risk factors
steroid
treatment of neurologic disorder
vaccine
varicella zoster virus
viral infection

Click Here to return To Results